Clinical trial investigates oral MRGPRX2 antagonist in urticaria
The first patient has been treated in a Phase II trial of EVO756 in adults with chronic inducible urticaria (CIndU).
EVO756 is a highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2) and could offer the potential for once-daily oral administration without the side effects observed with other therapies.
MRGPRX2 can trigger IgE-independent activation (degranulation) via multiple ligands, which can lead to a variety of symptoms depending on the tissue that is affected.
Evommune’s pre-clinical data demonstrates that by blocking activation of MRGPRX2 via all disease relevant ligand categories, EVO756 can prevent the degranulation of mast cells.
“As we continue to execute on our clinical development plans for EVO756, we are commencing this Phase II trial in 15 study sites across the United States. CIndU patients have limited treatment options, and we believe a novel, highly potent, selective agent, that can be orally administered once daily, could provide patients with major therapeutic benefit,” said Mark Jackson, Vice President, Clinical Development at Evommune.
The trial is designed to evaluate the safety and efficacy of EVO756 in approximately 30 patients with either symptomatic dermographism or cold urticaria, the two most common forms of CIndU.
Efficacy endpoints include changes from baseline in disease specific provocation thresholds that are used as objective markers to quantify disease severity and response to treatment.
EVO756 will be administered orally, once daily, for four weeks, and will be evaluated for safety and efficacy at weekly visits during treatment, with patients serving as their own control.
Daniel Burge, Senior Vice President, Clinical Development at Evommune, added: “Following the success of our proof-of-concept study with EVO756 earlier this year, we are also on track to initiate a Phase IIb trial in chronic spontaneous urticaria in the second quarter of 2025.”
Diana Spencer, Senior Digital Content Editor, DDW
